Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMDL wins clearance to market ELISA DR-70 blood test
The FDA clearance to market was based upon data showing DR-70 (FDP) has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy
The FDA clearance to market was based upon data showing DR-70 (FDP) has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy
Light Sciences Oncology (LSO) plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the US as well as a 40-patient, Phase IIa study in
With receipt of this license, the company has completed the acquisition of 63.3% of Shanghai Rongheng Pharmaceutical. Shanghai Rongheng International Trade of Orient International, CAS Shanghai Shenglongda Biotech
The in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention in the liver and heart.
Previously, Dr Wotton served as CEO of Topigen Pharmaceuticals. Prior to joining Topigen, Dr Wotton served as head of global business development at SkyePharma. Dr Wotton has over
According to the company, the new version of the ClinQuick system includes a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform
The transaction was completed substantially under the original terms announced on April 1, 2008, which called for Church & Dwight to pay $380 million in cash at closing.
Relistor subcutaneous injection is indicated for opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to the usual laxative therapy has not
The Phase I trial (Study 201) underway at South Texas Accelerated Research Therapeutics in San Antonio, Texas is designed to assess the tolerability and pharmacokinetics of IMGN388 in
According to the company, the patents cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad